For the year ending 2025-12-31, EVFM has $20,274K in assets. $89,711K in debts. $578K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Restricted cash and cash equivalents | 578 | |||
| Trade accounts receivable, net | 12,480 | |||
| Inventories | 1,129 | |||
| Prepaid and other current assets | 1,097 | |||
| Total current assets | 15,284 | |||
| Property and equipment, gross | 534 | |||
| Less accumulated depreciation | 116 | |||
| Property and equipment, net | 418 | |||
| Operating lease right-of-use assets | 182 | |||
| Intangible asset, net (note 7) | 4,348 | |||
| Other noncurrent assets | 42 | |||
| Total assets | 20,274 | |||
| Accounts payable | 13,153 | |||
| Convertible notes-Baker Bros Notes | 20,097 | |||
| Convertible notes-Related Party | 1,352 | |||
| Convertible notes-Adjuvant Notes | 32,770 | |||
| Short-term debt | 147 | |||
| Accrued expenses | 1,292 | |||
| Accrued compensation | 2,587 | |||
| Operating lease liabilities current | 128 | |||
| Derivative liabilities | 1,006 | |||
| Contingent liabilities - current (note 7) | 272 | |||
| Other current liabilities | 12,016 | |||
| Total current liabilities | 84,820 | |||
| Operating lease liabilities - noncurrent | 54 | |||
| Contingent liabilities - noncurrent (note 7) | 4,837 | |||
| Total liabilities | 89,711 | |||
| Convertible and redeemable preferred stock | 4,899 | |||
| Common stock, 0.0001 par value 3,000,000,000 shares authorized 126,685,925 and 113,356,354 shares issued and outstanding as of and december 31, 2025 and 2024, respectively | 13 | |||
| Additional paid-in capital | 831,859 | |||
| Accumulated other comprehensive loss | -8,818 | |||
| Accumulated deficit | -897,390 | |||
| Total stockholders deficit | -74,336 | |||
| Total liabilities, convertible and redeemable preferred stock and stockholders deficit | 20,274 | |||
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)